- Date
- Edition INTERNATIONALUKAU
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money
69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.
Opportunities
+ You'll also receive our newsletter and other Opto emails in accordance with our privacy policy. This form is protected by reCaptcha
The Biotech Breakout
+443%
One stock's return in 2019
$729bn
IBB index predicted valuation by 2025
+370%
One stock's growth since its IPO in 1995
$280bn
One biotech behemoth's mammoth valuation
+57%
Vertex Pharmaceuticals' 5-year return
+26%
IBB3-month rally from October to December 2019
-36%
Nasdaq Biotech Index loss following 2015 bubble
Why the breakout?
Learn why biotech stocks started soaring, and which fundamentals have set the foundation for long-term growth
Who to watch?
Discover the market disruptors in this high-growth sector, as we identify the companies at the cutting edge of biotech innovation
How to trade?
Whether it's individual stocks or ETFs, we explore the variety of ways traders can get exposure to this exciting sector
ebook preview
Breakout biotech stocks, under the microscope
We explain the surging share prices, identify the disruptors set to topple traditional heavyweights, and highlight the current opportunities in this high-growth sector
+$150 billion
Free cash flow generated per year by top 20 biopharma firms
175%
Blueprint Medicines share price return since IPO
127 deals
Number of biotech company acquisitions in 2019
The SPDR S&P Biotech ETF has outpaced both the Health Care Select Sector SPDR fund and S&P 500 since 2017
We are OPTO
Trading intelligence for the serious trader
OPTO started with a simple idea: that markets cannot truly be understood through numbers alone. Every company, investor and executive plays a role in shaping the market from one day to the next. By telling their stories and understanding what drives them, OPTO’s analysis provides a more holistic picture of what truly moves markets – and what those cold, hard numbers really mean.
Website
60,000+ monthly visits
Quarterly magazine
Global circulation of 25,000
Free industry reports
7,000+ downloads
Exclusive events
London-based with industry experts
Leveraged ETFs are complex financial instruments that carry significant risks. Certain leveraged ETF's are only considered appropriate for experienced traders